Hoffmann-La Roche: Lupus Erythematosus, Systemic trials
The registry lists 14 Lupus Erythematosus, Systemic studies with Hoffmann-La Roche as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 5Phase 2 5Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisRecruitingNCT07629583Phase 1
- A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisRecruitingNCT07598396Phase 2
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus ErythematosusActive, not recruitingNCT04963296Phase 3Results posted
- An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusTerminatedNCT03407482Phase 2Results posted
- A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusCompletedNCT02908100Phase 2Results posted
- A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)TerminatedNCT00626197Phase 3Results posted
- A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)TerminatedNCT00539838Phase 3Results posted
- A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus ErythematosusTerminatedNCT00381810Phase 3Results posted
- A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus ErythematosusCompletedNCT00137969Phase 2/3Results posted
- A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)WithdrawnNCT06984341Phase 1
- A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus ErythematosusActive, not recruitingNCT05835986Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus ErythematosusCompletedNCT05155345Phase 1
- A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus ErythematosusCompletedNCT00962832Phase 2
- A Study of rhuMAb IFNalpha in Adults With Systemic Lupus ErythematosusCompletedNCT00541749Phase 1